Mitochondrial DNA (mtDNA) damage drives the progression of age-related diseases like Age-Related Macular Degeneration (AMD), Parkinson’s, and Alzheimer’s. These conditions lead to mitochondrial dysfunction, which results in insufficient energy production and cellular chaos. Traditional gene-editing tools have struggled to effectively target mtDNA, highlighting the need for innovative solutions that can restore mitochondrial function.
The Technology for Artificial mtDNA Delivery (TADD) involves using a nanoparticle-based system to deliver healthy, full-length mtDNA to damaged cells. The process restores mitochondrial function by replenishing the mtDNA in cells where it has been damaged due to aging or disease.
The team is seeking development and commercial partners to advance TADD into clinical trials and welcomes licensing opportunities, investments, and sponsored research programs to support the further development and scaling of this technology.
